HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
The HER-2/neu oncogene codes a protein of the family of epidermal growth factor receptors. The extracellular domain has a MW from 95-105 kDa and is shed into the blood. In some patients with malignant tumors there is a high expression of HER-2/neu connected with high levels of HER-2/neu protein in the serum. High concentrations signal aggressive growth, bad prognosis and shorter survival. The reference range lies between 4.0 and 14.0 ng/ml with a mean of 9.0 ng/ml. There is a significant difference of values between patients with and without metastases, but not between healthy people and patients without metastases. The advantage of this parameter lies in the early diagnosis of recurrence in the therapy of metastasizing breast carcinomas especially on treatment with Herceptin.
Schulze
Guntram
G
Institut für Labordiagnostik, HELIOS Klinikum Berlin, Hobrechtsfelder Chaussee 100, D-13125 Berlin, Germany. schulze@rrk-berlin.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D011237:Predictive Value of Tests; D012372:ROC Curve; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D012680:Sensitivity and Specificity; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab